ID   SCMC-RM2-1
AC   CVCL_A668
DR   Cell_Model_Passport; SIDM01634
DR   Wikidata; Q54952465
RX   PubMed=2323848;
RX   PubMed=23882450;
CC   Population: Japanese.
CC   Doubling time: 52 hours (PubMed=2323848).
CC   Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (from parent cell line).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C8971; Embryonal rhabdomyosarcoma
DI   ORDO; Orphanet_99757; Embryonal rhabdomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_A667 ! SCMC-RM2
SX   Female
AG   11Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 29-06-23; Version: 16
//
RX   PubMed=2323848; DOI=10.1002/ijc.2910450423;
RA   Hayashi Y., Sugimoto T., Horii Y., Hosoi H., Inazawa J.,
RA   Kemshead J.T., Inaba T., Hanada R., Yamamoto K., Gown A.M., Sawada T.;
RT   "Characterization of an embryonal rhabdomyosarcoma cell line showing
RT   amplification and over-expression of the N-myc oncogene.";
RL   Int. J. Cancer 45:705-711(1990).
//
RX   PubMed=23882450; DOI=10.3389/fonc.2013.00183;
RA   Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G.,
RA   Linardic C.M.;
RT   "Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research:
RT   utility and pitfalls.";
RL   Front. Oncol. 3:183.1-183.12(2013).
//